acute ischemic stroke
Conditions
Interventions
Experimental group:remote ischemic postcontioning
Control group:None
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis meets the diagnostic criteria of acute cerebral infarction in the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018", with local symptoms of acute cerebral infarction; and computed tomography or magnetic resonance imaging (MRI) examination to confirm patients with cerebral infarction; 2. Those who meet the inclusion criteria for intravenous alteplase in acute cerebral infarction and are treated with thrombolytic therapy within 4.5 hours of the onset of symptoms; 3. The National Institutes of Health Stroke Scale (NIHSS) baseline score = 4 points; 4. Independent daily life before the onset of symptoms, modified Rankine Scale (mRS) <= 2; 5. Stable vital signs, signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who have not been treated with thrombolytic therapy within 24 hours before enrollment; 2. Patients with progressive neurological disease within 24 hours before enrollment; 3. Cerebral veins are damaged and diseased; 4. The cause of cerebral infarction is aortic dissection, moyamoya disease; any known vasculitis disease; herpes zoster, varicella-zoster or other viral infections vascular disease; neurosyphilis; other intracranial infections; any increase in cerebrospinal fluid cells Related intracranial artery stenosis; radiation-induced angiopathy; muscle fiber dysplasia; sickle cell disease; neurofibromas; central nervous system benign vascular disease; postpartum vascular disease; patients with vasospasm or thrombosis. 5. Those who clearly have any of the following cardiogenic embolism related diseases: rheumatic mitral valve or aortic valve stenosis, artificial heart valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, egg Patent round foramen, left ventricular mural thrombus or valvular growth, congestive heart failure, bacterial endocarditis, or any other cardiovascular diseases that are not suitable for inclusion in the group; 6. Suffer from uncontrollable severe hypertension (after drug treatment, systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg); 7. Those who are expected to undergo major surgery within 30 days before enrollment or within 3 months after enrollment (including femoral artery, heart, aortic or carotid surgery); 8. The target disease vessel has received stent implantation, angioplasty or other related medical device treatments, or those who are expected to undergo the above treatment within 12 months after enrollment; 9. Those who are contraindicated for remote ischemia, such as severe soft tissue injury, fracture or vascular injury in the upper extremity, and peripheral vascular disease of the distal upper extremity; 10. Pregnant or lactating women; 11. Life expectancy <1 year; 12. Unwilling to be followed up or poor compliance with treatment; 13. Those who are participating in other clinical researches, or who have participated in other clinical researches within 3 months before joining the group, or who have participated in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stromal cell-derived factor-1;Vascular endothelial growth factor;CXCR4+CD34+cells;Nuclear magnetic resonance; | — |
Countries
China
Contacts
Public ContactFang Qi
the First Affiliated Hospital of Soochow University
Outcome results
None listed